{
  "pmcid": "12507096",
  "sha256": "ad3d31c61774a57f468f4cbddb39585fbee13b29e79deb02fe915601ae8a2e98",
  "timestamp_utc": "2025-11-09T22:31:11.082800+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 17.16893617021277,
    "reading_ease": 4.166923076923098,
    "word_count": 235
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Pafolacianine in Intraoperative Molecular Imaging for Lung Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomly assigned to surgery with or without intraoperative molecular imaging using a 10:1 ratio"
      },
      "Participants": {
        "score": 2,
        "evidence": "112 patients with suspected or biopsy-confirmed lung cancer scheduled for sublobar pulmonary resection"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to surgery with or without intraoperative molecular imaging"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the clinical utility of pafolacianine"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the proportion of participants experiencing a clinically significant event"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence, and allocation was concealed"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "112 patients with suspected or biopsy-confirmed lung cancer"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "A total of 102 participants were analysed, with 92 in the intervention group and 10 in the control group, using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Clinically significant events occurred in 53% of participants, significantly exceeding the prespecified limit of 10% (P < .0001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No drug-related serious adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}